Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05304156 | Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"(DYNHAEMICS) | unknown | — | 200 | Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| May 29, 2024 |
| clinicaltrials |
| NCT05395910 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis | unknown | Phase 1 | 36 | National University Hospital, SingaporeOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05493800 | Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT(Capella) | unknown | Phase 2 | 60 | MitoImmune TherapeuticsINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT06432556 | Study of Cellular Heterogeneity in Patients With Mastocytosis(MastCellHet) | unknown | N/A | 26 | University Hospital, ToulouseOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06433362 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 2 | 115 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT01305499 | A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 52 | Hetty CarrawayOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03275493 | CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | unknown | Phase 1 / Phase 2 | 40 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06429865 | Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma | unknown | N/A | 1,000 | Changhai HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT04000906 | PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis(Nab-PIPAC) | unknown | Phase 1 | 18 | University Hospital, GenevaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT05878028 | L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC | unknown | Phase 2 | 33 | Quanli GaoOTHER_GOV | 1 | May 23, 2024 | clinicaltrials |
| NCT06227156 | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT06424379 | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.(BCL6-RINHL) | unknown | — | 135 | Hospices Civils de LyonOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT03724500 | Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer | unknown | — | 65 | Chang Gung Memorial HospitalOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06424821 | Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC(LungCadX) | unknown | Phase 2 | 54 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04418154 | Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients(NeoTENNIS) | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05964101 | Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma(GALAXY-1) | unknown | Phase 2 | 25 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06422546 | A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC(pre-FLAME) | unknown | — | 950 | Beijing Cancer Prevention & Treatment SocietyOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06423144 | PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7 | unknown | — | 150 | Shanghai Zhongshan HospitalOTHER | 0 | May 21, 2024 | clinicaltrials |
| NCT06421571 | The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients(GR-CTCL_CL) | unknown | — | 40 | National and Kapodistrian University of AthensOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06421610 | OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. | unknown | Phase 1 | 20 | Odense University HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04480502 | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma(ENVASARC) | unknown | Phase 2 | 207 | Tracon Pharmaceuticals Inc.INDUSTRY | 2 | May 17, 2024 | clinicaltrials |
| NCT04909073 | Observational Study of Afatinib 30 mg Daily | unknown | — | 69 | National University Hospital, SingaporeOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05065346 | Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC | unknown | N/A | 79 | Alpha Tau Medical LTD.INDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT05189197 | A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06261008 | Interactive Telehealth Intervention to Increase Longitudinal Adherence to Repeat Faecal Immunochemical Test Screening | unknown | N/A | 370 | Chinese University of Hong KongOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06419244 | Myosteatosis in Oeso-gastric Cancer: Clinical Impacts | unknown | N/A | 50 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05024318 | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma(NAPSTER) | unknown | Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05934864 | Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST) | unknown | — | 1,000 | Ruijin HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06036563 | Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing | unknown | — | 3,200 | Air Force Military Medical University, ChinaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06410625 | Evaluation of Response by FLT PET in Mesothelioma(FLT-MM) | unknown | N/A | 25 | Ankara UniversityOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06415708 | Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma | unknown | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06416319 | Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)(PreAct) | unknown | N/A | 164 | Universitätsmedizin MannheimOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06417372 | Intraoperative Fluorescent Staining Combined With Microsurgery for Gliomas | unknown | — | 100 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT02613988 | Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas | unknown | N/A | 100 | Asan Medical CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT03188172 | MUK Nine b: OPTIMUM Treatment Protocol(MUKnineb) | unknown | Phase 2 | 95 | University of LeedsOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05075356 | iToBoS: Clinical Data Acquisition Study(iToBoS) | unknown | N/A | 600 | The University of QueenslandOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT05241106 | A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 15 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05396118 | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients | unknown | Phase 2 | 15 | Rigshospitalet, DenmarkOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05650580 | TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors | unknown | Phase 1 | 26 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05942456 | Soluble B7-H3 as a Biomarker for Osteosarcoma | unknown | — | 200 | Peking University People's HospitalOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06173999 | A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06412068 | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 0 | May 14, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 29, 2024source: clinicaltrials